LAINATE (June 16, 2011) Cosmo Pharmaceuticals S.p.A. (SIX: COPN) today announced that its Methylene Blue MMX® for the diagnosis of lesions, polyps and adenomas in the colon will be presented in a live transmission of an endoscopic procedure on June 16 to approximately 500 specialists from around the world present at the International Meeting for Advanced Gastroenterology Endoscopy at Humanitas Hospital in Milano/Italy.
The Methylene blue-MMX® tablet is an oral colon-release formulation in form of coated tablets, containing methylene blue. The tablets are formulated using Como’s patented multimatrix technology (MMX®) that allows the delivery of the active ingredient directly inside the colon. With this technology, the maximum local bioavailability of the active ingredient is achieved and, consequently, the biological effect is optimized. Patents have been filed and are pending.
Currently a phase II dose ranging study is being conducted by Prof A. Repici at the Istituto Clinico Humanitas in Rozzano/Italy with the intention of testing the colon staining efficacy of single increasing oral doses of Methylene Blue MMX modified release tablets administered to approximately 100 patients undergoing colonoscopy. This is a descriptive non comparative study.
Following the live transmission Cosmo will inform investors and the general public about immediate reactions to the presentation.